Trials / Completed
CompletedNCT03840993
Safety and Efficacy Study of MT-2990 in Women With Endometriosis
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of MT-2990 in Women With Endometriosis Experiencing Endometrial Related Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Tanabe Pharma America, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-2990 | over 16 weeks |
| DRUG | Placebo | over 16 weeks |
Timeline
- Start date
- 2019-01-15
- Primary completion
- 2021-05-13
- Completion
- 2021-10-05
- First posted
- 2019-02-15
- Last updated
- 2025-12-31
- Results posted
- 2024-07-10
Locations
51 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03840993. Inclusion in this directory is not an endorsement.